GLP-1 Research Tracker

Every clinical trial and published study on semaglutide, tirzepatide, and next-generation GLP-1 medications — curated with plain-language summaries.

234 studies tracked·6 compounds covered·Updated Jul 2026

Has results

Predicting Long-Term Weight Loss Using Self-Reported, Digitally Collected, Real-World Data After Initiation of Semaglutide for Overweight or Obesity.

semaglutide

Advances in therapyFeb 2026

Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes.

semaglutide

Medicina clinicaFeb 2026

Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.

semaglutidetirzepatide

Obesity research & clinical practiceFeb 2026

Efficacy of Dual Glucagon and GLP-1 Agonists as New Treatments for Type II Diabetes.

Mini reviews in medicinal chemistryFeb 2026

Type 2 Diabetes and Vascular Complications: Current Perspectives on Pathophysiology and Management Strategies.

Current pharmaceutical designFeb 2026

Glycaemic control remains central in type 2 diabetes mellitus management: key learnings from the latest International Diabetes Federation guidelines.

Diabetes research and clinical practiceFeb 2026

Clinical knowns and mechanistic unknowns: cardioprotection and inflammation modulation of GLP-1 receptor agonists and SGLT2 inhibitors.

The Canadian journal of cardiologyFeb 2026

Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.

tirzepatideretatrutide

Cardiology in reviewFeb 2026

Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist.

semaglutideliraglutide

Diabetes, obesity & metabolismFeb 2026

Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.

semaglutidetirzepatide

BMC medicineFeb 2026

Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.

Diabetes, obesity & metabolismFeb 2026

Post-semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system.

semaglutide

Diabetes, obesity & metabolismFeb 2026

Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.

tirzepatide

Diabetes, obesity & metabolismFeb 2026

Established and emerging pharmacologic options and unmet need in HFpEF and HFmrEF.

semaglutidetirzepatide

ESC heart failureFeb 2026

Association of GLP-1 Inhibitors with Cardiovascular Outcomes in Patients Undergoing Coronary Artery Bypass Surgery.

The Journal of thoracic and cardiovascular surgeryFeb 2026

GLP-1 agonists and the gut microbiome: A bidirectional relationship.

British journal of clinical pharmacologyFeb 2026

Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions.

JNCI cancer spectrumFeb 2026

GLP-1 RAs vs. SGLT2is: Divergent pathways of cardiovascular inflammation control in obesity-associated diabetes.

Annales d'endocrinologieFeb 2026

[Onset of type 1 diabetes after treatment with online-prescribed semaglutide].

semaglutide

Ugeskrift for laegerFeb 2026

Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis.

Diabetes therapy : research, treatment and education of diabetes and related disordersFeb 2026

Load more studies →

GLP-1 Research Tracker

Predicting Long-Term Weight Loss Using Self-Reported, Digitally Collected, Real-World Data After Initiation of Semaglutide for Overweight or Obesity.

Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes.

Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.

Efficacy of Dual Glucagon and GLP-1 Agonists as New Treatments for Type II Diabetes.

Type 2 Diabetes and Vascular Complications: Current Perspectives on Pathophysiology and Management Strategies.

Glycaemic control remains central in type 2 diabetes mellitus management: key learnings from the latest International Diabetes Federation guidelines.

Clinical knowns and mechanistic unknowns: cardioprotection and inflammation modulation of GLP-1 receptor agonists and SGLT2 inhibitors.

Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.

Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist.

Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.

Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.

Post-semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system.

Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.

Established and emerging pharmacologic options and unmet need in HFpEF and HFmrEF.

Association of GLP-1 Inhibitors with Cardiovascular Outcomes in Patients Undergoing Coronary Artery Bypass Surgery.

GLP-1 agonists and the gut microbiome: A bidirectional relationship.

Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions.

GLP-1 RAs vs. SGLT2is: Divergent pathways of cardiovascular inflammation control in obesity-associated diabetes.

[Onset of type 1 diabetes after treatment with online-prescribed semaglutide].

Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis.

Get Weekly Research Updates